 "Lupin CEO Vinita Gupta")
Lupin is focusing on its inhalation portfolio to grow its international business. The idea is to monetise the inhalation and respiratory pipeline developed for the US market to other regulated markets like Europe, Japan, China and Australia. Lupin’s CEO Vinita Gupta tells Sohini Das about the company’s global plans. Edited excerpts:
What are the major product launches lined up for the US?
Respiratory products have become a major growth driver for us in the US, albuterol in particular. It has ramped up well over the last few quarters and now has a meaningful market share of over 20 per cent. Similarly, in
